Your browser doesn't support javascript.
loading
MEN1 mutations mediate clinical resistance to menin inhibition.
Perner, Florian; Stein, Eytan M; Wenge, Daniela V; Singh, Sukrit; Kim, Jeonghyeon; Apazidis, Athina; Rahnamoun, Homa; Anand, Disha; Marinaccio, Christian; Hatton, Charlie; Wen, Yanhe; Stone, Richard M; Schaller, David; Mowla, Shoron; Xiao, Wenbin; Gamlen, Holly A; Stonestrom, Aaron J; Persaud, Sonali; Ener, Elizabeth; Cutler, Jevon A; Doench, John G; McGeehan, Gerard M; Volkamer, Andrea; Chodera, John D; Nowak, Radoslaw P; Fischer, Eric S; Levine, Ross L; Armstrong, Scott A; Cai, Sheng F.
Affiliation
  • Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Stein EM; Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.
  • Wenge DV; Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Singh S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Kim J; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Apazidis A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rahnamoun H; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Anand D; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Marinaccio C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Wen Y; Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.
  • Stone RM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Schaller D; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Mowla S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Xiao W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gamlen HA; In silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Stonestrom AJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Persaud S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ener E; Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cutler JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Doench JG; Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McGeehan GM; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Volkamer A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chodera JD; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Nowak RP; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Fischer ES; Genetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.
  • Levine RL; Syndax Pharmaceuticals, Waltham, MA, USA.
  • Armstrong SA; In silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Cai SF; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 615(7954): 913-919, 2023 03.
Article in En | MEDLINE | ID: mdl-36922589
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia / Proto-Oncogene Proteins / Drug Resistance, Neoplasm / Mutation Limits: Animals / Humans Language: En Journal: Nature Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia / Proto-Oncogene Proteins / Drug Resistance, Neoplasm / Mutation Limits: Animals / Humans Language: En Journal: Nature Year: 2023 Document type: Article Affiliation country: